Menu Search
Equities

CanSino Biologics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
CJH:FRA

CanSino Biologics Inc

Actions
  • Price (EUR)3.68
  • Today's Change0.018 / 0.49%
  • Shares traded30.00
  • 1 Year change+3.84%
  • Beta1.0423
Data delayed at least 15 minutes, as of Feb 06 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

CanSino Biologics Inc is a China-based company primarily engaged in the research and development, production, and commercialization of human vaccine products. The Company’s products and product pipeline under research include multiple vaccine varieties such as meningitis, pneumonia, diphtheria, tetanus, and pertussis (DPT), coronavirus disease 2019 (COVID-19), Ebola virus disease, poliomyelitis, herpes zoster, tuberculosis and others. The Company is also engaged in the research and development of pharmaceutical production processes. The Company conducts its business in the domestic and overseas markets.

  • Revenue in HKD (TTM)1.03bn
  • Net income in HKD-188.09m
  • Incorporated2009
  • Employees1.11k
  • Location
    CanSino Biologics IncWest District Biomedical Park, No. 185South Avenue, West District, EconomicTIANJIN 300457ChinaCHN
  • Phone+86 2 258213766
  • Fax+86 2 258213626
  • Websitehttps://www.cansinotech.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.